Self-Directed Brokerage Account

A Self-Directed Brokerage Account, within the context of an employer-sponsored 401k plan, is a specialized investment option that empowers participants to exercise greater control and flexibility over their retirement savings. Unlike traditional 401k accounts that offer a limited selection of investment choices, a Self-Directed Brokerage Account allows employees to access a broader range of investment opportunities, including stocks, bonds, mutual funds, exchange-traded funds (ETFs), and other securities.

In a Self-Directed Brokerage Account, participants can make independent investment decisions according to their individual risk tolerance, financial goals, and market insights. They can allocate a portion or the entirety of their 401k contributions into the available investment options offered by the brokerage platform, thus tailoring their retirement portfolio to suit their preferences.

Example 1: John, a savvy investor, wants to diversify his 401k beyond the mutual funds offered in the standard plan. He opts for a Self-Directed Brokerage Account, enabling him to invest in specific company stocks and ETFs.

Example 2: Sarah, an employee passionate about socially responsible investments, chooses a Self-Directed Brokerage Account to invest exclusively in sustainable funds and environmentally friendly companies.

Example 3: Michael, an experienced trader, takes advantage of the Self-Directed Brokerage Account to actively manage his portfolio, adjusting his investments based on market trends and economic indicators.

However, it is essential to consider that self-directed investing involves higher levels of responsibility and potential risks, as participants are solely accountable for their investment choices. Employers often provide educational resources and guidance to ensure employees can make informed decisions and maximize the benefits of a Self-Directed Brokerage Account within their 401k plan.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.